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Identification of residues in the BST-2 TM domain important for 
antagonism by HIV-1 Vpu using a gain-of-function approach
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The HIV-1 Vpu protein enhances the release of viral particles from the cell-surface in a cell-type 
specific manner. In the absence of Vpu, nascent virions remain tethered to the cell-surface 
in restricted cell-types. Recently, the human host factor BST-2/CD317/tetherin was found 
to be responsible for the inhibition of virus release. It was also reported that HIV-1 Vpu can 
target human BST-2 but is unable to interfere with the function of murine or simian BST-2. We 
performed a gain-of-function study to determine which of the differences between human 
and rhesus BST-2 account for the differential sensitivity to Vpu. We transferred human BST-2 
sequences into rhesus BST-2 and assessed the resulting chimeras for inhibition of HIV-1 virus 
release and sensitivity to Vpu. We found that rhesus BST-2 carrying the transmembrane (TM) 
domain of human BST-2 is susceptible to HIV-1 Vpu. Finally, a single-amino-acid change in the 
rhesus BST-2 TM domain was sufficient to confer Vpu sensitivity.
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siRNA silencing of BST-2 rendered virus release from HeLa cells 
Vpu-independent (Neil et al., 2008; Van Damme et al., 2008; Rong 
et al., 2009). Taken together these data provided strong evidence 
that BST-2 was indeed the host factor whose inhibitory effect on 
virus release was counteracted by Vpu.
BST-2 is a 30- to 36-kDa type II integral membrane protein, 
consisting of 180 amino acids (Ishikawa et al., 1995). The protein 
has an N-terminal transmembrane (TM) domain and is presumed 
to contain a C-terminal glycosyl-phosphatidylinositol (GPI) anchor 
(Kupzig et al., 2003; Figure 1A). BST-2 protein associates with lipid 
rafts at the cell-surface and on internal membranes, presumably 
the trans-Golgi network (TGN; Kupzig et al., 2003; Dube et al., 
2009; Masuyama et al., 2009). X-ray crystallography of recombinant 
BST-2 demonstrated that residues 47–148 of the protein’s ectodo-
main can fold into a 90-Å parallel coiled-coil structure (Hinz et al., 
2010). In addition, small-angle X-ray scattering analyses predicted 
that the complete extracellular region of BST-2 adopts a long bent 
rodlike structure that separates the TM domain and GPI anchor 
by approximately 170 Å (Hinz et al., 2010).
Biochemical analyses demonstrated that BST-2 forms stable 
cysteine-linked dimers (Goto et al., 1994; Ohtomo et al., 1999; 
Andrew et al., 2009; Perez-Caballero et al., 2009) and is modified 
by N-linked glycosylation (Ohtomo et al., 1999; Kupzig et al., 2003; 
Andrew et al., 2009). The formation of cysteine-linked dimers can 
be catalyzed by any one of three cysteine residues in the BST-2 
ectodomain. Interestingly, BST-2 dimerization was not essential for 
BST-2 cell-surface expression or sensitivity to Vpu but is critical for 
inhibition of HIV-1 release (Andrew et al., 2009; Perez-Caballero 
et al., 2009). The functional role of BST-2 glycosylation on the other 
hand is still debated (Andrew et al., 2009; Perez-Caballero et al., 
2009; Sakuma et al., 2009a).
IntroductIon
Efficient virus release from HIV-infected cells is regulated by its 
Vpu gene product (Strebel et al., 1988; Terwilliger et al., 1989). 
However, the dependence on Vpu for efficient virus release is cell-
type dependent (Sakai et al., 1995), leading investigators to pre-
dict the presence of a host restriction factor in Vpu-dependent 
cell-types (Varthakavi et al., 2003). Interestingly, IFN-treatment 
of Vpu-independent cell-types created a Vpu-dependent pheno-
type and inhibited not only the release of HIV-1 and related ret-
roviruses but also affected secretion of unrelated viruses such as 
porcine endogenous retrovirus (PERV), Ebola, Lassa, Marburg, 
endogenous betaretrovirus of sheep (enJSRV), and KSHV (Neil 
et al., 2007; Jouvenet et al., 2009; Kaletsky et al., 2009; Sakuma 
et al., 2009b; Arnaud et al., 2010; Mattiuzzo et al., 2010). These 
observations suggested that the Vpu-sensitive restriction factor 
was not specific to HIV but belonged to a family of interferon-
inducible genes with general antiviral properties. In the course of a 
quantitative membrane proteomics study, Vpu was found to reduce 
cellular expression of BST-2 in HeLa cells (Bartee et al., 2006). 
Subsequent reports identified BST-2 as the IFN-inducible, Vpu-
sensitive factor responsible for the restriction of HIV-1 virus release 
(Neil et al., 2008; Van Damme et al., 2008). Indeed, BST-2 expres-
sion was cell-type dependent. BST-2 was constitutively expressed 
in Vpu-dependent cell-types such as HeLa, Jurkat, or CD4+ T cells 
but was undetectable in cell-types such as 293T or HT1080 cells 
and thus corresponded to cell-types known to depend on Vpu for 
efficient virus release (Neil et al., 2008; Van Damme et al., 2008). 
Importantly, BST-2 expression was induced by interferon treatment 
in 293T and HT1080 cells (Neil et al., 2007, 2008) and ectopic 
expression of BST-2 in 293T or HT1080 cells rendered these cells 
Vpu-dependent (Neil et al., 2008; Van Damme et al., 2008). Finally, 
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primers 5′-ATAAC TCGAG GTGGA ATTCA TGGCA CCTAT 
TTTGT ATGAC and 3′-ATATT GGTAC CTCAC AGCAG CAGAG 
CGCTC AAGCC CAGCA GCAG. The rhesus macaque RNA was 
isolated from a pool of activated PBMC of eight rhesus macaques. 
The resulting PCR product was cleaved with XhoI and KpnI and 
cloned into the XhoI/KpnI sites of pcDNA3.1(−) (Invitrogen Corp., 
Carlsbad, CA, USA). The nucleotide sequence of cloned cDNAs 
was verified by sequence analysis.
AntIserA
Anti-BST-2 antiserum was elicited in rabbits using a bacterially 
expressed MS2-BST-2 fusion protein composed of amino acids 
1–91 of the MS2 replicase (Strebel et al., 1986) and amino acids 
41–162 of BST-2 generating a polyclonal antibody against the extra-
cellular portion of BST-2. The antibody was found to react with 
human as well as rhesus BST-2. Polyclonal anti-Vpu serum (rabbit), 
directed against the hydrophilic C-terminal cytoplasmic domain 
of Vpu expressed in Escherichia coli (Maldarelli et al., 1993) was 
used for detection of Vpu. Serum from an HIV-positive patient was 
used to detect HIV-1-specific capsid (CA) and Pr55gag precursor 
proteins. Tubulin was identified using a monoclonal antibody to 
α-tubulin (Sigma-Aldrich, Inc., St. Louis, MO, USA).
tIssue culture And trAnsfectIons
293T cells were propagated in Dulbecco’s modified Eagles medium 
(DMEM) containing 10% fetal bovine serum (FBS). For transfec-
tion, cells were grown in 25 cm2 flasks to about 80% confluency. 
Cells were transfected using TransIT® LT-1 (Mirus, Madison, WI, 
USA) following the manufacturer’s recommendations. A total of 
5.2 μg of plasmid DNA per 25 cm2 flask was used. Total amounts 
of transfected DNA was kept constant in all samples of any given 
experiment by adding empty vector DNA as appropriate. Cells were 
harvested 24 h post-transfection.
MetAbolIc lAbelIng And IMMunoprecIpItAtIons
Cells were transfected as described in the text with constant amounts 
of proviral vectors and increasing amounts of BST-2. Twenty-four 
hours later, cells were washed with PBS, scraped, and resuspended in 
3 ml labeling media lacking methionine (Millipore Corp., Billerica, 
MA, USA). Cells were then incubated for 10 min at 37°C to deplete 
the endogenous methionine pool. Cells were then suspended in 
400 μl of labeling medium together with 150 μCi of Express 35S35S 
protein labeling mix (Perkin Elmer, Shelton, CT, USA). Cells were 
labeled for 90 min at 37°C. Cells and virus-containing supernatants 
were then separated by centrifugation and processed separately for 
immunoprecipitation as follows: Cells were lysed with 150 μl of 
Triton lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% Triton-
X100) and incubated on ice for 5 min. After lysis, the cells were 
pelleted at 13,000×g for 2 min to remove insoluble material. The 
supernatants were used for immunoprecipitation. Virus-containing 
supernatants were treated with 150 μl of Triton lysis buffer to dis-
rupt viral membranes. Cell and virus lysates were adjusted to 1.1 ml 
total volume with PBS containing BSA (final concentration of BSA: 
0.1%) and incubated on a rotating wheel for 1 h at 4°C with protein 
A-Sepharose coupled with an HIV-positive patient serum. Beads 
were washed twice with wash buffer (50 mM Tris pH 7.4, 300 mM 
NaCl, 0.1% Triton X-100). Bound proteins were eluted by  heating 
Vpu and BST-2 are both integral membrane proteins albeit 
with different membrane topologies. BST-2 has a short N-terminal 
cytoplasmic domain with the bulk of the protein comprising the 
C-terminal ectodomain. Vpu, on the other hand, has virtually no 
ectodomain, and essentially consists of an N-terminal TM domain 
and a C-terminal cytoplasmic domain. Recent data suggest that 
the BST-2 TM domain is critical for interference by Vpu (Douglas 
et al., 2009; Dube et al., 2009; Gupta et al., 2009; McNatt et al., 
2009; Mitchell et al., 2009; Perez-Caballero et al., 2009; Rong et al., 
2009) consistent with our previous observation of the importance 
of the Vpu TM domain for the regulation of virus release (Schubert 
et al., 1996). Indeed, physical interaction of Vpu and BST-2 and 
the critical importance of the BST-2 TM domain for this interac-
tion was demonstrated in the course of co-immunoprecipitation 
studies (Douglas et al., 2009; Gupta et al., 2009; Iwabu et al., 2009; 
Jia et al., 2009; McNatt et al., 2009; Rong et al., 2009; Dube et al., 
2010) and bimolecular fluorescence complementation analyses 
(Kobayashi et al., 2011). Infection of cells by wild type (wt) virus 
results in the redistribution of BST-2 from the plasma membrane 
to early endosomes (Neil et al., 2006; Habermann et al., 2010). 
This involves internalization of BST-2 through clathrin-dependent 
endocytosis (Rollason et al., 2007; Masuyama et al., 2009; Mitchell 
et al., 2009). As for Vpu, the protein is predominantly localized to 
membranes of the Golgi and TGN (Klimkait et al., 1990; Schubert 
et al., 1996; Varthakavi et al., 2006) and was found to colocalize 
with BST-2 in endosomes and the TGN (Rollason et al., 2007; Neil 
et al., 2008; Van Damme et al., 2008; Douglas et al., 2009; Dube 
et al., 2009). Furthermore, Vpu mutants affected in TGN localiza-
tion were unable to antagonize BST-2 suggesting that Vpu targets 
BST-2 in this compartment (Dube et al., 2009). However, Vpu was 
also identified at the cell-surface (Bour et al., 1999) and a direct 
effect of Vpu on cell-surface BST-2 cannot be ruled out. In fact, 
one recent study proposed that Vpu targets BST-2 at the plasma 
membrane (Iwabu et al., 2009).
The current study aims at further analyzing the regions in 
BST-2 that define sensitivity to Vpu. Our approach was to trans-
fer sequences from human BST-2 into the Vpu-resistant rhesus 
BST-2 to check function and Vpu sensitivity of the resulting chi-
mera. Interestingly, mutation of a single residue in rhesus BST-2 
(I48T) was sufficient to significantly increase sensitivity to Vpu. 
These results are consistent with a recent report demonstrating that 
mutation of T45 in human BST-2 (which is the equivalent of I48 in 
rhesus BST-2) was sufficient to render human BST-2 significantly 
less sensitive to Vpu (Gupta et al., 2009). These results suggest that 
resistance or sensitivity of BST-2 isolates to Vpu can be regulated 
by relatively subtle changes in BST-2.
MAterIAls And Methods
plAsMIds
The full length infectious HIV-1 molecular clone pNL4-3 and the 
Vpu deletion mutant pNL4-3/Udel have been described (Adachi 
et al., 1986; Klimkait et al., 1990). For transient expression of Vpu, 
the codon-optimized vector pcDNA–Vphu (Nguyen et al., 2004) 
was employed. Plasmid pcDNA–BST-2 is a vector for the expres-
sion of human BST-2 under the control of the cytomegalovirus 
immediate-early promoter (Andrew et al., 2009). Rhesus BST-2 
was amplified by RT-PCR from rhesus macaque RNA using the 
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“Materials and Methods.” Four independent clones were 
sequenced and aligned against the GenBank entry of Macaca 
mulatta (GenBank NM_001161666). We also included in our 
alignment the sequences of three recently described rhesus 
macaque isolates (McNatt et al., 2009; Figure 1A). Interestingly, 
rhesus BST-2 exhibited sequence polymorphism at five positions 
(residues 9, 14, 29, 111, and 159). Two polymorphic sites each 
were located in the protein’s cytoplasmic and ecto-domains; one 
polymorphic site mapped to the TM domain (highlighted in black 
in sample buffer for 10 min at 95°C, separated by SDS-PAGE, and 
visualized by fluorography. Virus release was quantified by phos-
pho-image analysis using a Fujifilm FLA7000 system.
results
clonIng of rhesus bst-2
Pooled RNA from eight rhesus macaques was used for RT-PCR 
amplification of BST-2 and the resulting cDNA was cloned 
in untagged form into pcDNA3.1(−) as described in Section 
FIgure 1 | Cloning, expression, and Vpu sensitivity of rhesus BST-2. 
(A) Rhesus BST-2 was cloned from pooled rhesus macaque RNA by RT-PCR as 
described in Section “Materials and Methods.” Four independent clones (rh 
BST-2 #1 to rh BST-2 #4) were sequenced and aligned against the GenBank 
entry for Macaca mulatta BST-2 (top row). Sequences of three recently 
published rhesus BST-2 variants [Mac(m)1 to Mac(m)3; McNatt et al., 2009] 
were coaligned for comparison. Amino acid identities are indicated as dots. 
Amino acid differences are marked by black boxes. (B) Expression of rh BST-2 
variants was assessed by transfecting 293T cells with 1 μg each of hu BST-2 or 
rh BST-2 vectors in the presence or absence of pcDNA–Vphu (1 μg). Total 
amounts of transfected DNA were adjusted to 5 μg using empty vector DNA. 
Transfected cells were harvested 24 h later and whole cell extracts were 
subjected to immunoblotting using a polyclonal antibody to human BST-2 (Miyagi 
et al., 2009). Note that this antibody cross-reacts with rhesus BST-2.
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rhesus bst-2 cArryIng the tM doMAIn of huMAn bst-2 Is 
susceptIble to hIV-1 Vpu
Several previous studies concluded that the BST-2 TM domain is 
critical for sensitivity to Vpu (Goffinet et al., 2009; Gupta et al., 
2009; Iwabu et al., 2009; McNatt et al., 2009; Rong et al., 2009; 
Dube et al., 2010). However, in two of these studies (Goffinet et al., 
2009; Dube et al., 2010) transfer of the human TM domain to 
African green monkey (agm), murine, or rat BST-2 did not restore 
sensitivity to Vpu while in a third study (McNatt et al., 2009) 
transfer of the human BST-2 TM domain into agm and rhesus 
BST-2 resulted in gain of Vpu sensitivity. To further characterize 
the determinants of human BST-2 required for susceptibility to 
Vpu, we used a similar gain-of-function approach by transferring 
portions of human BST-2 into the Vpu-resistant rhesus BST-2 
variant #4. For that purpose we generated a series of rhesus BST-2 
chimeras as illustrated in Figure 3A. The design of the chimera 
was based on regions of sequence diversity between human and 
rhesus BST-2 (Figure 3B). Expression of chimeric BST-2 proteins 
was determined by immunoblotting (Figure 3C). Each chimera 
was analyzed for gain of Vpu sensitivity. Virus release in the pres-
ence or absence of Vpu was determined by metabolic labeling as 
described for Figure 2A. The results are shown in Figure 4. We 
found that only chimera 4 and chimera 7 containing parts or all 
of the human BST-2 TM domain gained significant sensitivity to 
Vpu. All other chimeras inhibited virus release irrespective of the 
presence or absence of Vpu. The fact that all chimera inhibited 
virus release indicates that the synthesis and trafficking of these 
proteins was comparable to the parental wt proteins. The finding 
that transfer of residues 30–45 of human BST-2 into rhesus BST-2 
(chimera 4) is sufficient to confer sensitivity to Vpu indicates that 
sequences critical to Vpu sensitivity are located in the C-terminal 
part of the BST-2 TM domain.
A sIngle-AMIno-AcId chAnge renders rhesus bst-2 pArtIAlly 
susceptIble to hIV-1 Vpu
The region of human BST-2 transferred into chimera 4 differs from 
rhesus BST-2 in six amino acid positions (Figure 5A). To analyze the 
importance of each of these residues to Vpu sensitivity, we generated 
additional chimeras containing single-amino-acid changes relative 
to the parental rhesus BST-2 variant. Each of the six amino acid 
positions was altered individually resulting in chimeras G33V, V36I, 
L39I, L43P, F46I, and I48T, respectively (Figure 5A). Expression of 
the variants was confirmed by immunoblotting (Figure 5B). Finally, 
we assessed the susceptibility of these mutants by metabolic labeling 
as shown for Figure 2 (Figure 6). Interestingly, mutation of I48T 
induced partial sensitivity of rhesus BST-2 to Vpu, especially at 
low levels of BST-2. In contrast, all other mutants remained fully 
Vpu-resistant. Thus, mutation of the rhesus BST-2 TM domain at 
position 48 from isoleucine to threonine was sufficient to render 
rhesus BST-2 partially susceptible to Vpu.
dIscussIon
CD4 degradation and regulation of virus release, which are the two 
best-studied functions of Vpu, involve distinct structural domains 
of Vpu (Schubert et al., 1996). The ability to degrade CD4 is criti-
cally dependent on Vpu’s cytoplasmic domain, and in particular a 
in Figure 1A). In fact, all four rhesus BST-2 clones were differ-
ent from each other and from the GenBank entry, and only one 
of our clones (rh BST-2 #3) was identical to one of three rhesus 
variants described previously [Figure 1A; Mac(m)2]. We tested 
expression and sensitivity to Vpu-induced degradation of all four 
rhesus BST-2 variants in transfected 293T cells and found no 
striking differences (Figure 1B). As reported previously, transient 
transfection of cells with BST-2 vectors results in the production 
of a dominant protein species of ∼29 kDa representing imma-
ture BST-2 carrying high-mannose carbohydrate modifications 
(Andrew et al., 2009). In addition, a diffuse pattern of proteins 
from 30 to 40 kDa is evident in Figure 1B, representing mature 
forms of BST-2 containing complex carbohydrate modifications 
(Andrew et al., 2009). Consistent with previous observations, 
human BST-2 levels were partially reduced in the presence of 
Vpu (Figure 1B, compare lanes 1 and 2) while rhesus BST-2 levels 
remained essentially unaltered in the presence or absence of Vpu 
(Figure 1B, lanes 3–10). We empirically chose rhesus BST-2 clone 
#4 for all subsequent functional studies.
hIV-1 Vpu counterActs huMAn but not rhesus bst-2
To further understand the susceptibility of BST-2 to HIV-1 Vpu we 
compared the ability of human BST-2 and rhesus BST-2 to inhibit 
release of wt and Vpu-deficient (Udel) HIV-1. The human kidney 
cell line 293T, which does not express detectable levels of endog-
enous BST-2 and does not inhibit release of Vpu-deficient HIV-1 
(Neil et al., 2008; Van Damme et al., 2008; Miyagi et al., 2009) was 
used to assess the effects of transiently expressed human or rhesus 
BST-2 on the release of wt NL4-3 and Vpu-deficient NL4-3/Udel 
viruses. We started out by comparing the dose-dependent effects 
of untagged human and rhesus BST-2 on virus release (Figure 2A). 
For that purpose 293T cells were transfected with wt pNL4-3 or 
pNL4-3/Udel (5 μg each) in the absence or presence of increasing 
amounts of human or rhesus BST-2 (0–0.2 μg plasmid DNA as 
indicated in Figure 2B). Twenty-four hour post-transfection, cells 
were metabolically labeled for 90 min and cell and viral extracts 
were immunoprecipitated using an HIV-positive patient serum. 
Proteins were visualized by fluorography (Figure 2A) and quanti-
fied by phospho-image analysis (Figure 2B). The ratio of virus 
associated Gag protein relative to the total intra- and extracellu-
lar Gag was determined and plotted as a function of BST-2 DNA 
concentration (Figure 2B). As expected, human and rhesus BST-2 
inhibited release of NL4-3 Udel virus in a dose-dependent manner 
(Figure 2B, open circles), In addition, we found that rhesus BST-2 
inhibited the release of wt NL4-3 as efficiently as Vpu-deficient 
virus (Figure 2B, bottom; solid circles). In contrast, Vpu was able 
to counteract the inhibitory effect of human BST-2 (Figure 2B, top, 
solid circles); however, human BST-2 also inhibited the release of 
wt NL4-3 at higher levels of expression consistent with previous 
reports (Van Damme et al., 2008). Relative expression of human 
and rhesus BST-2 was determined by immunoblotting (Figure 2C). 
As expected, transfection of increasing amounts of plasmid DNA 
resulted in a dose-dependent increase in BST-2 expression. These 
results indicate that release of HIV-1 virions from 293T cells is 
inhibited by both human and rhesus BST-2; however, only human 
BST-2 could be counteracted by HIV-1 Vpu.
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FIgure 2 | HIV-1 Vpu counteracts human but not rhesus BST-2. (A) 293T cells 
were transfected with 5 μg of either pNL4-3 (wt) or pNL4-3/Udel (Udel) in the 
absence of BST-2 (lanes 1 and 5) or in the presence of 0.01 μg (lanes 2 and 6), 
0.05 μg (lanes 3 and 7), or 0.2 μg (lanes 4 and 8) human (top panel) or rhesus 
(bottom panel) BST-2. Metabolic labeling was carried out as described in the text 
and cell lysates and cell-free supernatants were subjected to immunoprecipitation 
using an HIV-positive pooled human serum. Samples were separated by 
SDS-PAGE and proteins were visualized by fluorography. (B) Gag-specific cellular 
and viral proteins (Pr55 and p24) were quantified by phospho-image analysis. Solid 
circles represent samples expressing NL4-3; open circles represent NL4-3/Udel. 
The amount of p24 released in the absence of BST-2 relative to the total intra- and 
extracellular Gag protein was defined as 100%. Virus release in the presence of 
increasing amounts of BST-2 was calculated accordingly and the results were 
plotted as a function of transfected BST-2 DNA. (C) Expression of BST-2 was 
analyzed by immunoblotting. 293T cells were transfected with 0 (lanes 1 and 5), 
0.01 (lanes 2 and 6), 0.05 (lanes 3 and 7), or 0.2 μg (lanes 4 and 8) of human BST-2 
or rhesus BST-2 as in (A). Total amounts of transfected DNA were adjusted to 5 μg 
using empty vector DNA as appropriate. Whole cell lysates were prepared 24 h 
after transfection and subjected to immunoblot analysis using a BST-2 specific 
antibody as described in Figure 1B.
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involvement of the Vpu and CD4 TM domains (Buonocore et al., 
1994; Raja et al., 1994; Magadan et al., 2010). However, the con-
tribution of the TM domains for CD4-Vpu interaction appears to 
be relatively non-specific since the TM domains of both proteins 
can be replaced by heterologous TM domains without loss of CD4 
degradation (Willey et al., 1994; Bour et al., 1995; Hout et al., 2005, 
2006). Also, scrambling the Vpu TM domain had virtually no effect 
di-phosphoserine motif, which is necessary for the assembly of an 
ubiquitin ligase complex that ultimately marks CD4 for degradation 
by the cellular proteasome machinery (reviewed in Strebel, 2007; 
Andrew and Strebel, 2010). Although critical elements involved in 
the binding of Vpu to CD4 have been mapped to the Vpu and CD4 
cytoplasmic domains (Raja et al., 1994; Willey et al., 1994; Yao et al., 
1995; Tiganos et al., 1997) some reports have noted an additional 
FIgure 3 | Construction and analysis of rhesus–human BST-2 chimeras. 
(A) Schematic diagram of BST-2 chimeras. The black bar represents rhesus BST-2 
and the gray bar indicates human BST-2. Regions from human BST-2 inserted into 
the rhesus BST-2 backbone are indicated as gray areas. Boundaries of cytoplasmic 
domain, TM domain, and ectodomain are marked by dashed lines. (B) Alignment of 
human and rhesus BST-2. Shown is an alignment of human BST-2 against rhesus 
BST-2 variant #4. Sequence identities are indicated as dots. Deletions are marked 
as dashes. Amino acid changes in rhesus BST-2 relative to human BST-2 are 
indicated in white on black background. Regions swapped in chimeras are boxed or 
marked by brackets. The TM domain is indicated as a shaded area. (C) Expression 
of BST-2 chimeras was analyzed by immunoblotting. 293T cells were transfected 
with 1 μg each of human BST-2, rhesus BST-2, or chimera 1–7 as indicated. Total 
amounts of transfected DNA were adjusted to 5 μg using empty vector DNA as 
appropriate. Whole cell lysates were prepared 24 h after transfection and subjected 
to immunoblot analysis using a BST-2 specific antibody as described in Figure 1B. 
A mock-transfected sample was included as a negative control (Ctrl).
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for inhibition by Vpu. Unlike the Vpu–CD4 interaction, however, 
the sequence of the BST-2 domain is critical for functional inter-
action with Vpu. The data presented here supports two previous 
studies showing that transfer of the TM domain of human BST-2 
to normally Vpu-insensitive non-human BST-2 variants confers 
partial or full Vpu sensitivity (McNatt et al., 2009; Rong et al., 
2009). It remains unclear why two other studies did not observe 
a gain of Vpu sensitivity following transfer of the human BST-2 
TM domain into agm or rodent BST-2 (Goffinet et al., 2009; Dube 
on the ability of Vpu to degrade CD4 (Schubert et al., 1996) sug-
gesting that the primary sequence of the Vpu TM domain is not 
critical for this function.
On the other hand, the structural integrity of the Vpu TM 
domain appears to be critical for the enhancement of virus release 
(Schubert et al., 1996; Paul et al., 1998) and for the interference of 
Vpu with BST-2 function. Because of the importance of the Vpu 
TM domain for regulating virus release, it was not particularly 
surprising that the TM domain of BST-2 was equally important 
FIgure 4 | Analysis of rhesus BST-2 carrying the TM domain of human 
BST-2 for susceptibility to HIV-1 Vpu. 293T cells were transfected with 5 μg of 
either pNL4-3 (wt) or pNL4-3/Udel (Udel) in the absence of BST-2 or in the 
presence of 0.01, 0.05, or 0.2 μg BST-2 chimeric constructs as described for 
Figure 2A. Metabolic labeling analysis was carried out as described for 
Figure 2A. Representative fluorographs are shown. Quantitation of virus release 
is shown on the right of each panel and was performed as described in the 
legend to Figure 2B. Error bars reflect SEM from two independent experiments.
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FIgure 5 | Construction of BST-2 point mutants. (A) Sequence alignment 
of BST-2 TM domain region encompassed by chimera 4. Chimera 4, which is 
Vpu-sensitive, contains six amino acid differences with respect to rhesus 
BST-2. Each of the six positions was changed individually to the corresponding 
human sequence by PCR-based site-directed mutagenesis. Dots represent 
sequence identities. Amino acid positions at the top refer to rhesus BST-2. 
Numbers listed at the bottom refer to the corresponding human BST-2 amino 
acid positions. (B) Expression of BST-2 point mutants was verified by 
immunoblotting as described for Figure 3C.
et al., 2010). However, it is interesting to note that the latter two 
studies employed BST-2 constructs carrying an N-terminal HA 
tag while the partially Vpu-sensitive construct used by Rong et al. 
(2009) carried an N-terminal Flag tag. The fully Vpu-sensitive 
construct described by McNatt et al. (2009) carried an internal 
HA tag while our own fully sensitive construct was untagged. It 
seems therefore possible that differences in the Vpu sensitivity 
of BST-2 chimeras carrying the human BST-2 TM domain are 
attributable to the presence of epitope tags in different locations 
of the protein.
Analysis of the TM domains of human and rhesus BST-2 
revealed a number of differences including a deletion of two 
amino acids near the N-terminus of the rhesus BST-2 TM domain 
as well as six single-amino-acid differences in the C-terminal 
half of the TM domain (Figure 5A). The importance of these 
differences in the TM domains of human and rhesus BST-2 for 
Vpu sensitivity has been addressed in several previous studies 
(Gupta et al., 2009; McNatt et al., 2009; Rong et al., 2009; Dube 
et al., 2010). However, all of these studies conducted loss-of-
function analyses, meaning that mutations were introduced into 
the Vpu-sensitive human BST-2 and the resulting chimeras were 
tested for loss of Vpu sensitivity. In contrast, our own strategy 
was a gain-of-function approach which involved the introduction 
of human BST-2 sequences into the backbone of Vpu-resistant 
rhesus BST-2 and measuring resulting chimeras for gain of 
Vpu sensitivity. In addition, our experiments were done using 
untagged protein species. Previous studies agree that deletion 
of a GI amino acid motif present in human BST-2 but absent in 
non-human BST-2 variants, combined with mutation of T45I, 
resulted in complete loss of Vpu sensitivity. Mutation of T45I 
alone was found to induce partial loss of Vpu sensitivity (Gupta 
et al., 2009; McNatt et al., 2009; Rong et al., 2009). The impor-
tance of a di-leucine motif near C-terminal end of the human 
BST-2 TM domain is unclear. Deletion of the di-leucine motif 
was found to abolish sensitivity to Vpu (Rong et al., 2009) while 
mutation - rather than deletion - of the same motif had only a 
partial effect on Vpu sensitivity (McNatt et al., 2009). Our own 
results demonstrate that transfer of the N-terminal segment of 
the human BST-2 TM domain containing the di-leucine motif 
as well as the GI motif did not confer Vpu sensitivity to the 
resulting chimera (Figure 4, chimera 2), thus suggesting that 
the di-leucine and GI elements may be necessary but are not 
sufficient to establish Vpu sensitivity. With respect to individual 
point mutations (Figure 6), our gain-of-function data agree with 
previous loss-of-function analyses in that most changes of indi-
vidual amino acids had little or no impact on Vpu sensitivity 
(Gupta et al., 2009; McNatt et al., 2009; Rong et al., 2009). Our 
results disagree with previous studies in that mutation of G33V 
(corresponding to V30G in human BST-2 Gupta et al., 2009; 
McNatt et al., 2009; Rong et al., 2009) did not confer resistance 
to Vpu in our analysis (Figure 6) while mutation of that residue 
in human BST-2 resulted in a partial loss of Vpu sensitivity. 
Finally, mutation of I48T in rhesus BST-2 conferred partial Vpu 
sensitivity in our gain-of-function approach, consistent with the 
partial loss of Vpu sensitivity of the corresponding I45T mutant 
in human BST-2 reported previously (Gupta et al., 2009; McNatt 
et al., 2009; Rong et al., 2009).
Taken together our data demonstrate that transfer of indi-
vidual residues (i.e., I48T in Figure 6) or parts of the human 
BST-2 TM domain (i.e., chimera 4 in Figure 4) can confer partial 
Vpu sensitivity to rhesus BST-2. Thus, the BST-2 TM domain 
contains the determinants responsible for the species-specific 
sensitivity to Vpu. How the interaction of Vpu and BST-2 leads 
to the functional inactivation of BST-2 remains to be investi-
gated. Co-immunoprecipitation and bimolecular fluorescence 
complementation analyses suggest a direct physical interaction 
of Vpu and BST-2 (Rong et al., 2009; Dube et al., 2010; Kobayashi 
et al., 2011). However, binding of Vpu to BST-2 may not be suf-
ficient to neutralize BST-2 and to ensure efficient virus release 
since at least in one case, transfer of the human TM domain 
conferred Vpu interaction but did not bestow Vpu sensitivity to 
agm BST-2 (Dube et al., 2010). It was previously shown that the 
physical interaction of CD4 and HIV-1 Env in the endoplasmic 
reticulum can prevent the trafficking of CD4 and HIV-1 Env 
to the cell-surface (Crise et al., 1990; Jabbar and Nayak, 1990; 
Bour et al., 1991). Future studies will have to address the pos-
sibility that the physical association of Vpu and BST-2 similarly 
imposes a trafficking defect leading to the depletion of BST-2 
from the cell-surface.
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